EVA is powered by the new Cellvizio software, today available for sale in Europe and in the USA for digestive, pulmonary and urological applications*.
EVA enables efficient management of Optical Biopsy procedures with greater workflow productivity, clinical value and integration:
- An increased confidence for physicians using Cellvizio: EVA's SmartReview™ highlights the stable segments within Cellvizio videos for a streamlined Optical Biopsy procedure review. Moreover, with FastExtract™, EVA permits an immediate selection of the video clips identified by SmartReview™. Finally, EVA's Atlas provides reference videos for each organ and pathology, directly available on the Cellvizio system.
- A way to share Cellvizio within the hospital: EVA's DICOM connectivity facilitates integration of Cellvizio into the hospital information system for digital archiving and transmission of Optical Biopsy data all over the hospital. With QuickReport™, through an easy-to-use template, EVA generates print-ready reports for the patient’s electronic health record.
- An improved access to Cellvizio: through a redesigned user interface, EVA allows physicians to make annotations on images, and provides a remote service solution for better assistance.
”This impressive improvement will significantly facilitate our usage of Optical Biopsy”, commented Dr. David Carr-Locke, Chief, Division of Digestive Diseases, Beth Israel Medical Center, New York, an early adopter of the Cellvizio system who helped design EVA. “With EVA, I believe that endoscopy and surgery will never be the same again.”
EVA's availability is the first milestone towards the launch of the expected “Smart Atlas”, a unique extensive library of Optical Biopsy references coupled to a proprietary image recognition algorithm, which will assist the physicians in their Optical Biopsy interpretation.
“Mauna Kea Technologies has always made integration and physician's confidence a top priority, as both are critical to the adoption of Optical Biopsy. Our development efforts are aligned towards making Optical Biopsy a standard of care procedure”, said Sacha Loiseau, CEO of Mauna Kea Technologies. “Starting today, EVA will enhance the endoscopic and surgical experience, and engage physicians on a deeper, more impactful level in the way they use Optical Biopsy for managing their patients.”
For more information, please check the following webpage: http://www.maunakeatech.com/patients/47/product-spotlight
Press release avilable from http://www.businesswire.com/